Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065531 | 0.68 | AHR (0.52) | — | |
| SCHEMBL767109 | 0.65 | NOS1 (0.55) | — | |
| SCHEMBL4276905 | 0.65 | CYP1A2 (0.46) | — | |
| SCHEMBL9739407 | 0.65 | KDM4E (0.40) | — | |
| SCHEMBL28584478 | 0.65 | HTR2A (0.41) | HTR2AHTR2CHTR2B | |
| SCHEMBL9742121 | 0.61 | ALDH1A1 (0.34) | — | |
| SCHEMBL14746132 | 0.61 | RHEB (0.47) | — | |
| Phosphoric Acid SCHEMBL6130379 | 0.61 | AHR (0.43) | — | |
| SCHEMBL208744 | 0.60 | LMNA (0.51) | — | |
| SCHEMBL1444295 | 0.60 | ALDH1A1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741593-B2 | Method for releasing a product comprising chemical oxidation, method for detecting said product and uses thereof | PROTEUS (FR) | 2014-06-03 | — | — | US | claimed |
| EP-1285086-B1 | METHOD FOR LIBERATING A PRODUCT COMPRISING A CHEMICAL OXYDATION, DETECTION OF THE PRODUCT AND FURTHER APPLICATIONS | PROTEUS (FR) | 2013-07-03 | — | — | EP | claimed |
| EP-1691779-A4 | TREATMENT OF A CONDITION IN A MAMMAL WITH ADMINISTRATION OF COMPOUNDS AND METHODS OF USE THEREOF | OPTIMER PHARMACEUTICALS INC (US) | 2009-01-21 | — | — | EP | claimed |
| US-20070099257-A1 | Method for releasing a product comprising chemical oxidation, method for detecting said product and uses thereof | PROTEUS (FR) | 2007-05-03 | — | — | US | claimed |
| US-20070082851-A1 | Treatment of a condition in a mammal with administration of Compounds and Methods of Use | OPTIMER PHARMACEUTICALS INC. (US) | 2007-04-12 | — | — | US | claimed |
| EP-1691779-A2 | TREATMENT OF A CONDITION IN A MAMMAL WITH ADMINISTRATION OF COMPOUNDS AND METHODS OF USE THEREOF | Optimer Pharmaceuticals, Inc. (US) | 2006-08-23 | — | — | EP | claimed |
| WO-2005051326-A2 | TREATMENT OF A CONDITION IN A MAMMAL WITH ADMINISTRATION OF COMPOUNDS AND METHODS OF USE THEREOF | OPTIMER PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | WO | claimed |
| US-20030199017-A1 | Method for releasing a product comprising chemical oxidation, method for detecting said product and uses thereof | PROTEUS | 2003-10-23 | — | — | US | claimed |
| EP-1285086-A2 | METHOD FOR DETECTING A DETECTABLE PRODUCT | Proteus (FR) | 2003-02-26 | — | — | EP | claimed |
| WO-2001092563-A2 | METHOD FOR DETECTING A DETECTABLE PRODUCT | PROTEUS (FR) | 2001-12-06 | — | — | WO | claimed |
| EP-0495346-B1 | Procedure for separation, identification, and quantification of isoenzymes and isoforms of the alkaline phosphatase | ANALIS SA (BE) | 1996-05-15 | — | — | EP | claimed |
| EP-2588219-B1 | FILTER PLATE ARTICLE HAVING A WATER-ABSORBENT FILTER ASSEMBLY | NEOGEN FOOD SAFETY US HOLDCO CORP (US) | 2024-05-29 | — | — | EP | disclosed |
| US-11892450-B2 | Evaluation, assays and treatment of pKal-mediated disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-06 | — | — | US | disclosed |
| CN-116096240-A | Lactic acid bacteria composition for preparing fermented food | 科·汉森有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-11618880-B2 | Compositions comprising bacterial strains and use thereof in controlling pathogenic microorganisms | BETTER AIR INTERNATIONAL LIMITED (HK) | 2023-04-04 | — | — | US | disclosed |
| US-5958675-A | Method for detecting bacteria using bacteriophage, contrast-coloring dye and precipitable dye | 3M INNOVATIVE PROPERTIES COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
| US-5843742-A | Adeno-associated derived vector systems for gene delivery and integration into target cells | AVIGEN INCORPORATED (US) | 1998-12-01 | — | — | US | disclosed |
| WO-1998048042-A2 | METHODS AND DEVICES FOR DETECTING BACTERIOPHAGE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-10-29 | — | — | WO | disclosed |
| US-5292669-A | Chromogenic agent, oxidizer | BOEHRINGER MANNHEIM GMBH (DE) | 1994-03-08 | — | — | US | disclosed |
| US-4327073-A | IMMOBILIZATION AND USE OF RADIOACTIVE TRACERS | KENDREW BIOSYSTEMS, INC., A CORP. OF DE | 1982-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199017-A1 | Method for releasing a product comprising chemical oxidation, method for detecting said product and uses thereof | CBR1, AOX1, MPO | HTR2A 1170/4885HTR2C 788/4885HTR2B 570/4885 |
| US-20070082851-A1 | Treatment of a condition in a mammal with administration of Compounds and Methods of Use | AADAT, MMP1, MMP13 | HTR2A 1260/4885HTR2C 1775/4885HTR2B 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.